Advances And New Perspectives in the Treatment of Metastatic Colon Cancer

World Journal of Gastrointestinal Oncology

Volumn 6, Issue , 2014, Pages 211-224

  Recondo, Gonzalo ^a   Díaz Cantón, Enrique ^a,b   de la Vega, Máximo ^a,b   Greco, Martin ^a   Valsecchi, Matias E ^c  

^a CEMIC   (Argentina)

^b Fundacion para Combatir La Leucemia   (Argentina)

^c Huntington Internal Medicine Group   (United States)

Author keywords

Bevacizumab; Cetuximab; Colon Cancer; flibercept; Metastatic; Panitumumab; Regorafenib; Review; Stage IV

Indexed keywords

EID: 84916206160     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i7.211     Document Type: Article

References (88)

1. 1 Jemal A, Center MM, DeSantis C, Ward EM. Global pat¬terns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-1907 [PMID: 20647400 DOI: 10.1158/1055-9965.EPI-10-0437]
2. 2 Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tab- ernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351 [PMID: 15175436 DOI: 10.1056/NEJMoa032709]
3. 3 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 [PMID: 12778165 DOI: 10.1038/nm0603-669]
4. 4 Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591 [PMID: 18596824 DOI: 10.1038/nrc2403]
5. 5 Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre¬metastatic niche. Nature 2005; 438: 820-827 [PMID: 16341007 DOI: 10.1038/nature04186]
6. 6 Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005; 103: 1561-1570 [PMID: 15754332 DOI: 10.1002/cncr.20942]
7. 7 Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. Effect of antivascular endothelial growth factor treatment on the in- tratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-1986 [PMID: 12799646 DOI: 10.1038/sj.bjc.6601005]
8. 8 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Hol-mgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovo¬rin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
9. 9 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011; 30: 682-689 [PMID: 21959045 DOI: 10.5732/cjc.011.10188]
10. 10 Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treat¬ment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786 [PMID: 17947725 DOI: 10.1200/JCO.2007.11.3357]
11. 11 Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrim¬idines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690 [PMID: 18235136 DOI: 10.1200/JCO.2007.15.5390]
12. 12 Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitch¬ell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovo¬rin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544 [PMID: 17442997 DOI: 10.1200/JCO.2006.09.6305]
13. 13 Saltz LB, Clarke S, D^az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in meta¬static colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/ JCO.2007.14.9930]
14. 14 Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hain- sworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorec¬tal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529 [PMID: 18640933 DOI: 10.1200/JCO.2007.15.4138]
15. 15 Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and effica¬cy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847 [PMID: 19406901 DOI: 10.1093/annonc/mdp233]
16. 16 Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addi¬tion of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a random¬ized phase II trial. J Clin Oncol 2005; 23: 3697-3705 [PMID: 15738537 DOI: 10.1200/JCO.2005.05.112]
17. 17 Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, beva- cizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointesti¬nal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198 [PMID: 20516443 DOI: 10.1200/ JCO.2009.27.7723]
18. 18 Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously un¬treated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085 [PMID: 24028813 DOI: 10.1016/S1470-2045(13)70154-2]
19. 19 Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramana- than RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovo¬rin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30 [PMID: 14665611 DOI: 10.1200/ JCO.2004.09.046]
20. 20 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of in- fusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leu¬covorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0928]
21. 21 Falcone A, Cremolini C, Masi G, Lonardi S, Zagonel V, Sal¬vatore L, Trenta P, Tomasello G, Ronzoni M, Ciuffreda L, Zaniboni A, Tonini G, Buonadonna A, Valsuani C, Chiara S, Carlomagno C, Boni C, Marcucci L, Boni L, Loupakis F. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal can¬cer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. ASCO Meeting Abstracts 2013; 31: 3505
22. 22 Gruenberger T, Bridgewater JA, Chau I, Garcia Alfonso P, Rivoire M, Lasserre S, Waterkamp D, Adam R. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLF- OXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. ASCO Meeting Abstracts 2013; 31: 3619
23. 23 Gaya A, Tse V. A preclinical and clinical review of afliber-cept for the management of cancer. Cancer Treat Rev 2012; 38: 484-493 [PMID: 22264850 DOI: 10.1016/j.ctrv.2011.12.008]
24. 24 Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yan- copoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398 [PMID: 12177445 DOI: 10.1073/pnas.172398299]
25. 25 Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways re¬sults in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008; 7: 3747-3758 [PMID: 19029832]
26. 26 Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap com-bined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005; 11: 6966-6971 [PMID: 16203789 DOI: 10.1158/1078-0432.CCR-05-0910]
27. 27 Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP. VEGF trap in com¬bination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007; 67: 1526-1537 [PMID: 17234361 DOI: 10.1016/j.ijrobp.2006.11.011]
28. 28 Van Cutsem E, Khayat D, Verslype C, Billemont B, Tejpar S, Meric JB, Soussan-Lazard K, Assadourian S, Cartot-Cotton S, Rixe O. Phase I dose-escalation study of intravenous afliber- cept administered in combination with irinotecan, 5-fluo- rouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 2013; 49: 17-24 [PMID: 22921183 DOI: 10.1016/j.ejca.2012.07.007]
29. 29 V an Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and iri¬notecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506 [PMID: 22949147 DOI: 10.1200/JCO.2012.42.8201]
30. 30 Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvi¬ronment. Biomed Res Int 2013; 2013: 546318 [PMID: 23986907 DOI: 10.1155/2013/546318]
31. 31 Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardi- ello F. Cetuximab plus irinotecan, fluorouracil, and leucovo¬rin as first-line treatment for metastatic colorectal cancer: up¬dated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]
32. 32 Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Ba- rugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treat¬ment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJ- Moa1305275]
33. 33 Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003 [PMID: 12006511]
34. 34 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
35. 35 Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048 [PMID: 18003960 DOI: 10.1056/NEJMoa071834]
36. 36 Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitu- mumab plus best supportive care compared with best sup¬portive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
37. 37 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as ini¬tial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJ- Moa0805019]
38. 38 Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/ JCO.2008.20.8397]
39. 39 Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Ba- rugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Ran¬domized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with pre¬viously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]
40. 40 Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680 [PMID: 19114685 DOI: 10.1200/JCO.2008.19.8135]
41. 41 Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sin- nige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572 [PMID: 19196673 DOI: 10.1056/NEJMoa0808268]
42. 42 Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206 DOI: 10.1158/0008-5472. CAN-04-1443]
43. 43 Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimio- ara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Mi- lanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-336 [PMID: 15711537 DOI: 10.1038/nbt1068]
44. 44 Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255 [PMID: 21170960 DOI: 10.1002/ijc.25864]
45. 45 Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 2658-2667 [PMID: 22421192 DOI: 10.1158/1078-0432. CCR-11-1900]
46. 46 Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Regorafenib (BAY 73-4506) in advanced colorec¬tal cancer: a phase I study. Br J Cancer 2012; 106: 1722-1727 [PMID: 22568966 DOI: 10.1038/bjc.2012.153]
47. 47 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Rego- rafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicen¬tre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/S0140- 6736(12)61900-X]
48. 48 Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13: 51-64 [PMID: 18245012 DOI: 10.1634/theoncologist.2007-0142]
49. 49 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch- Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215 [PMID: 24120480 DOI: 10.1016/S1470-2045(13)70447-9]
50. 50 Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Mar- tignoni G, Bouche O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911 [PMID: 18794541 DOI: 10.1200/ JCO.2008.17.3781]
51. 51 Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zie¬linski C, Herbst F, Gruenberger T. Bevacizumab, capecitabi- ne, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835 [PMID: 18398148 DOI: 10.1200/ JCO.2007.13.7679]
52. 52 Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neo¬adjuvant treatment of unresectable liver disease with irino¬tecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939 [PMID: 15151951]
53. 53 Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Ma¬honey MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249 [PMID: 16230673 DOI: 10.1200/JCO.2005.07.740]
54. 54 Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour re-sponse and secondary resectability of colorectal liver metas¬tases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47 [PMID: 19942479 DOI: 10.1016/S1470-2045(09)70330-4]
55. 55 Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of ce¬tuximab plus chemotherapy for patients with KRAS wild¬type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938 [PMID: 23569301 DOI: 10.1200/ JCO.2012.44.8308]
56. 56 Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. A multicentre study of capecitabine, oxaliplatin plus bevaci- zumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront re-section. Ann Oncol 2011; 22: 2042-2048 [PMID: 21285134 DOI: 10.1093/annonc/mdq714]
57. 57 Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorec¬tal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17: 2059-2065 [PMID: 20177795 DOI: 10.1245/s10434-010-0972-9]
58. 58 Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorec¬tal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142 [PMID: 17630036 DOI: 10.1016/ S0140-6736(07)61086-1]
59. 59 Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line com¬bination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/ S0140-6736(11)60613-2]
60. 60 Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrho- nen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkham- mar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continu¬ous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762 [PMID: 22473155 DOI: 10.1200/ JCO.2011.38.0915]
61. 61 Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon J, Yu H, Go WY. PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorec¬tal cancer (mCRC). ASCO Meeting Abstracts 2013; 31: 446
62. 62 Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmuel- ler J, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Schaefer B, Modest DP, Jung A, Stintzing S. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first- line treatment of KRAS-wildtype metastatic colorectal can¬cer: German AIO study KRK-0306 (FIRE-3). ASCO Meeting Abstracts 2013; 31: LBA3506
63. 63 Stintzing S, Jung A, Rossius L. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first- line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. See more at: Presented at: Sep 27-Oct 1, 2013. Amsterdam, The Netherlands: European Cancer Congress, 2013: Abstract LBA17
64. 64 Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24 [PMID: 10772661 DOI: 10.1172/JCI8829]
65. 65 Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334 [PMID: 18854571 DOI: 10.1200/JCO.2008.16.3212]
66. 66 Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Stef¬fens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andre T, Kubicka S. Continuation of bevaci- zumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 [PMID: 23168366 DOI: 10.1016/S1470-2045(12)70477-1]
67. 67 von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Luck HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast can¬cer. Eur J Cancer 2011; 47: 2273-2281 [PMID: 21741829 DOI: 10.1016/j.ejca.2011.06.021]
68. 68 Grothey A, Sargent D. Overall survival of patients with ad¬vanced colorectal cancer correlates with availability of fluo¬rouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441-9442 [PMID: 16361649 DOI: 10.1200/ JCO.2005.04.4792]
69. 69 Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. So¬matic mutations of EGFR in colorectal cancers and glioblas¬tomas. N Engl J Med 2004; 351: 2883 [PMID: 15625347 DOI: 10.1056/NEJM200412303512724]
70. 70 Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochem¬istry. J Clin Oncol 2005; 23: 1803-1810 [PMID: 15677699 DOI: 10.1200/JCO.2005.08.037]
71. 71 Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase II study of erlotinib (OSI-774) in patients with meta¬static colorectal cancer. Br J Cancer 2006; 94: 1136-1143 [PMID: 16570047 DOI: 10.1038/sj.bjc.6603055]
72. 72 Santoro A, Comandone A, Rimassa L, Granetti C, Lorusso V, Oliva C, Ronzoni M, Siena S, Zuradelli M, Mari E, Pressiani T, Carnaghi C. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 1888-1893 [PMID: 18667394 DOI: 10.1093/annonc/mdn401]
73. 73 Tournigand C, Samson B, Scheithauer W, Lledo G, Viret F, Andre T, Ramee JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Khalil A, Latreille J, Louvet C, Brusquant D, Bonnetain F, Chibaudel B, De Gramont A, GERCOR. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemo¬therapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the Internation¬al GERCOR DREAM phase III trial. ASCO Meeting Abstracts 2012; 30: LBA3500
74. 74 Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO Meeting Abstracts 2010; 28: 3534
75. 75 Higgins B, Kolinsky KD, Schostack K, Bollag G, Lee RJ, Su F, Packman K. Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combina¬tion with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model. ASCO Meeting Abstracts 2012; 30: 494
76. 76 Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010; 56: 229-239 [PMID: 20102402 DOI: 10.1111/j.1365-2559.2009.03468.x]
77. 77 Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261 [PMID: 20100961 DOI: 10.1200/ JCO.2009.24.6116]
78. 78 Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606 [PMID: 23094721 DOI: 10.1056/NEJMoa1207756]
79. 79 Bendell JC, Ervin TJ, Senzer NN, Richards DA, Firdaus I, Lockhart AC, Cohn AL, Saleh MN, Gardner LR, Sportelli P, Eng C. Results of the X-PECT study: A phase III random¬ized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2012; 30: LBA3501
80. 80 Hochster HS, Messersmith WA, O'Neil BH, Groshen SG, Cohen DJ, Denlinger CS, Gold PJ, Eckhardt SG, Locker GY, Ames P, McKinley M, Leichman LP, Academic GI Can¬cer Consortium. Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study. ASCO Meeting Abstracts 2013; 31: 380
81. 81 Barbara C, Martin V, Molinari F, Landi L, Riva A, Saletti P, de Dosso S, Geva R, Tejpar S, Fountzilas G, Kalogeras KT, Frattini M, Cappuzzo F. Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies. ASCO Meeting Abstracts 2012; 30: 474
82. 82 Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: over¬coming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013; 13: 241-255 [PMID: 23281932 DOI: 10.1517/14 712598.2012.756469]
83. 83 Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus bevaci- zumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, random¬ized phase III study (HORIZON III). J Clin Oncol 2012; 30: 3588-3595 [PMID: 22965961 DOI: 10.1200/JCO.2012.42.5355]
84. 84 Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F. Van- detanib: An overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc) 2010; 46: 683-698 [PMID: 20967300 DOI: 10.1358/dot.2010.46.9.1516989]
85. 85 Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JM, Moore MJ, Cervantes-Ruiperez A, Asmis TR, Schwartz JD, Ballal S, Tabernero J. A phase II, open-label study evaluating the safe¬ty and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorec¬tal cancer (mCRC): CP12-0709/NCT00862784. ASCO Meeting Abstracts 2012; 30: 533
86. 86 Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loup-akis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S. Insulin-like growth factor 1 expression correlates with clini¬cal outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010; 127: 1941-1947 [PMID: 20099280 DOI: 10.1002/ijc.25193]
87. 87 O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gul¬ley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with ad-vanced malignancy. Clin Cancer Res 2007; 13: 958-964 [PMID: 17289891 DOI: 10.1158/1078-0432.CCR-06-1974]
88. 88 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 [PMID: 22658127 DOI: 10.1056/NEJMoa1200690]